BR9504791A - Composto polipeptídeo processo para preparação de um composto polipeptídeo composição farmacêutica medicamento e método para tratamento profilático e/ou terapêutico de doenças infecciosas - Google Patents

Composto polipeptídeo processo para preparação de um composto polipeptídeo composição farmacêutica medicamento e método para tratamento profilático e/ou terapêutico de doenças infecciosas

Info

Publication number
BR9504791A
BR9504791A BR9504791A BR9504791A BR9504791A BR 9504791 A BR9504791 A BR 9504791A BR 9504791 A BR9504791 A BR 9504791A BR 9504791 A BR9504791 A BR 9504791A BR 9504791 A BR9504791 A BR 9504791A
Authority
BR
Brazil
Prior art keywords
polypeptide compound
prophylactic
preparing
pharmaceutical composition
infectious diseases
Prior art date
Application number
BR9504791A
Other languages
English (en)
Other versions
BR9504791B1 (pt
Inventor
Hidenori Ohki
Masaki Tomishima
Akira Yamada
Hisashi Takasugi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9504791(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9504791A publication Critical patent/BR9504791A/pt
Publication of BR9504791B1 publication Critical patent/BR9504791B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI9504791-3A 1994-10-07 1995-10-06 composto de polipeptìdeo e composição farmacêutica. BR9504791B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound

Publications (2)

Publication Number Publication Date
BR9504791A true BR9504791A (pt) 1996-10-22
BR9504791B1 BR9504791B1 (pt) 2010-10-05

Family

ID=26305774

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9504791-3A BR9504791B1 (pt) 1994-10-07 1995-10-06 composto de polipeptìdeo e composição farmacêutica.
BRPI9504791A BRPI9504791B8 (pt) 1994-10-07 1995-10-06 composto de polipeptídeo e composição farmacêutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9504791A BRPI9504791B8 (pt) 1994-10-07 1995-10-06 composto de polipeptídeo e composição farmacêutica.

Country Status (27)

Country Link
US (2) US6107458A (pt)
EP (1) EP0788511B1 (pt)
JP (2) JP2897427B2 (pt)
KR (1) KR100353303B1 (pt)
CN (1) CN1203089C (pt)
AR (1) AR041770A1 (pt)
AT (1) ATE229541T1 (pt)
AU (1) AU696949B2 (pt)
BR (2) BR9504791B1 (pt)
CA (1) CA2202058C (pt)
DE (2) DE122008000025I2 (pt)
DK (1) DK0788511T3 (pt)
ES (1) ES2187575T3 (pt)
FI (1) FI119988B (pt)
FR (1) FR08C0028I2 (pt)
HK (1) HK1004136A1 (pt)
HU (1) HU228151B1 (pt)
IL (1) IL115484A (pt)
LU (1) LU91452I2 (pt)
MX (1) MX9702531A (pt)
NL (1) NL300352I2 (pt)
NO (2) NO328483B1 (pt)
OA (1) OA10475A (pt)
PT (1) PT788511E (pt)
RU (1) RU2165423C2 (pt)
TR (1) TR199501229A2 (pt)
WO (1) WO1996011210A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998057923A1 (fr) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. Nouveau procede de preparation
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
JP3561917B2 (ja) * 1998-02-09 2004-09-08 藤沢薬品工業株式会社 新規化合物
ES2251976T3 (es) * 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
DE60040989D1 (de) 1999-07-27 2009-01-15 Aventis Pharma Gmbh Cyclohexapeptide, deren herstellung und verwendung in pharmazeutische zusammensetzungen
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP4784093B2 (ja) * 2002-08-08 2011-09-28 アステラス製薬株式会社 イソオキサゾリル安息香酸の製造法
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2298821T3 (es) 2003-07-22 2008-05-16 Theravance, Inc. Utilizacion de un agente antifungico de equinocandina en combinacion con un agente antibacteriano glicopeptidico.
WO2005026323A2 (en) * 2003-09-05 2005-03-24 Merck & Co., Inc. Stationary phases and a purification process using the stationary phases
CN1902177A (zh) * 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US7868033B2 (en) * 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515478A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP1815206B1 (en) * 2004-10-13 2016-04-06 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2007043400A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
HUE036086T2 (hu) 2007-08-13 2018-06-28 Monsanto Technology Llc Készítmények és eljárások nematódák irtására
US20100256048A1 (en) * 2007-10-29 2010-10-07 Astellas Pharma Inc. Polypeptide compound
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
CN102076670B (zh) * 2008-06-24 2013-05-22 Irm责任有限公司 调节g蛋白偶联受体的化合物和方法
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
CA2832145C (en) 2011-04-20 2020-10-20 Xellia Pharmaceuticals Aps Method for purification of micafungin
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
HUE029720T2 (en) * 2011-09-09 2017-03-28 Sandoz Ag Preparation of micafungin intermediates
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102659930B (zh) * 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
EP3150623B1 (en) * 2014-05-29 2019-04-03 Shanghai Techwell Biopharmaceutical Co., Ltd Solvate of cyclic peptide compound, preparation method for same, and uses thereof
EP3226885A4 (en) * 2014-10-07 2018-07-18 Alaparthi, Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN108752430B (zh) * 2018-05-31 2022-02-18 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
CZ288974B6 (cs) * 1992-03-19 2001-10-17 Eli Lilly And Company Acylový derivát echinocandinu, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a jeho pouľití

Also Published As

Publication number Publication date
JPH10324695A (ja) 1998-12-08
HU228151B1 (en) 2012-12-28
NL300352I1 (nl) 2008-08-01
NO2010016I1 (no) 2010-08-16
KR970707150A (ko) 1997-12-01
HK1004136A1 (en) 1998-11-20
KR100353303B1 (ko) 2003-01-15
MX9702531A (es) 1997-06-28
LU91452I2 (fr) 2008-08-04
DK0788511T3 (da) 2003-03-31
EP0788511A1 (en) 1997-08-13
AU3578095A (en) 1996-05-02
ES2187575T3 (es) 2003-06-16
TR199501229A2 (tr) 1996-07-21
NO328483B1 (no) 2010-03-01
CN1168675A (zh) 1997-12-24
JP2897427B2 (ja) 1999-05-31
OA10475A (en) 2002-04-08
US6265536B1 (en) 2001-07-24
AU696949B2 (en) 1998-09-24
US6107458A (en) 2000-08-22
WO1996011210A1 (en) 1996-04-18
NO971544L (no) 1997-06-04
CA2202058C (en) 2007-11-06
JP3518665B2 (ja) 2004-04-12
EP0788511B1 (en) 2002-12-11
RU2165423C2 (ru) 2001-04-20
CN1203089C (zh) 2005-05-25
FR08C0028I1 (pt) 2008-08-15
DE122008000025I1 (de) 2008-08-21
NO2010016I2 (no) 2011-10-17
FI119988B (fi) 2009-05-29
BR9504791B1 (pt) 2010-10-05
DE69529172D1 (de) 2003-01-23
FI971397A0 (fi) 1997-04-04
BRPI9504791B8 (pt) 2019-12-31
AR041770A1 (es) 2005-06-01
DE69529172T2 (de) 2003-04-17
IL115484A (en) 2000-07-16
NO971544D0 (no) 1997-04-04
NL300352I2 (nl) 2008-11-03
FI971397A (fi) 1997-05-27
HUT77736A (hu) 1998-07-28
IL115484A0 (en) 1996-01-19
FR08C0028I2 (pt) 2009-11-20
ATE229541T1 (de) 2002-12-15
CA2202058A1 (en) 1996-04-18
PT788511E (pt) 2003-04-30
DE122008000025I2 (de) 2011-02-17
JPH10507174A (ja) 1998-07-14

Similar Documents

Publication Publication Date Title
BR9504791A (pt) Composto polipeptídeo processo para preparação de um composto polipeptídeo composição farmacêutica medicamento e método para tratamento profilático e/ou terapêutico de doenças infecciosas
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR9602542A (pt) Composto método para o tratamento de uma doença dependente da fosforilase de glicogénio composição farmacéutica e processo para a preparação de um composto
BR9601200A (pt) Composto e seus sais e prodragas farmaceuticamente acetiáveis processo para a preparação de um composto método e composição farmacêutica para o tratamento de doenças hiperproliferativas
BR9303014A (pt) Composto,composicao farmaceutica,metodo de tratamento de doencas neurolepticas e processo para a preparacao do composto
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
PT98944A (pt) Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes
FI941979A (fi) Farmaseuttiset tuotteet kasvainsairausten hoitamiseksi ja menetelmä niiden valmistamiseksi
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9507656A (pt) Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
AU7383687A (en) Pharmaceutical preparations containing formoterol or its salts, and a method of treating skin diseases
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9506473A (pt) Composto processo para a preparação de compostos utilização de um composto composição farmacêutica e processo para o tratamento de infecções anti-fúngicas
BR9505610A (pt) Composto composição farmacéutica processo para a preparação de um composto uso e método de tratar inflamação e dor
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9504463A (pt) Processo para preparaçao de lipossomas de quetoprofeno e preparaçoes farmacêuticas
PT97749A (pt) Processo para a preparacao de composicoes farmaceuticas contendo dsarn apropriadas para o diagnostico e o tratamento de hepatite viral
BR9504090A (pt) Composição farmacêutica transdermicamente ativante processo para sua preparação e método de tratar câncer
BR9610316A (pt) Composto processo para a produção e uso do mesmo processo para o tratamento de doença das vias aéreas e composição farmacêutica
BR9600254A (pt) Composto processo para a sua preparação seus usos método para o tratamento de arritmias e medicamento contendo o mesmo
BR9510015A (pt) Composto composição farmacéutica e processo para o tratamento de doenças enfecciosas em terapia humana ou veterinária
BR9612206A (pt) Composto uso do composto composição farmacêutica processo para preparação do composto e para o tratamento da dor
HUT68007A (en) Pharmaceutical compositions for preventing and treating retinal diseases and process for preparing them

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B15K Others concerning applications: alteration of classification

Free format text: ALTERACAO DE CLASSIFICACAO DE C07K 7/64, C07K 1/36, C07K103/00, C07M 7/00, C07M 9/00, A61K 38/08 PARA : C07K 7/56, A61K 38/12 O PRESENTE PEDIDO REFERE-SE A PEPTIDEOS CICLICOS APRESENTANDO UMA LIGACAO PEPTIDICA ANORMAL; E COMPOSICOES.

Ipc: C07K 7/56, A61K 38/12

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061162/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132252-414.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: ASTELLAS PHARMA INC., AVENTIS PHARMA S.A, BIOCREA GMBH, BRACCO S.P.A, CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2074 DE 05/10/2010 QUANTO A DATA DE VALIDADE CONFORME DETERMINADO NO INPI 52400.061162/2013 SECAO JUDICIARIA DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0001999-28.2014.4.02.5101.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061162/2013 SECAO JUDICIARIA DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0001999-28.2014.4.02.5101 APELANTE: ASTELLAS PHARMA INC.APELADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: DEFIRO O REQUERIMENTO FORMULADO PELO INPI, DETERMINANDO A IMEDIATA CORRECAO DO PRAZO DE VIGENCIA DA PATENTE PI 9504791-3 PARA 05/10/2015.

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52400.061162/2013-38 NUP: 00408.030830/2018-16 (REF. 0001999-28.2014.4.02.5101) INTERESSADOS: INTERFARMA ASSOCIACAO DA INDUSTRIA FARMACEUTICA DE PESQUISA E OUTROS DECISAO: PELO EXPOSTO, DEFIRO O REQUERIMENTO FORMULADO PELO INPI, DETERMINANDO A IMEDIATA CORRECAO DO PRAZO DE VIGENCIA DA PATENTE PI9504791-3 PARA 06.10.2015.